Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POINTS: Cadonilimab + Chemo for Neoadjuvant ESCC
NCT06356688Phase 2Recruiting
- Start
- Apr 2025
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC). Started Apr 2025; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06356688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06356688.